FRANKLIN LAKES, N.J., April 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference on Tuesday, May 13, 2025 at 1:00 pm Eastern Time.The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the l ...

Core Insights - Robotic-assisted surgery is becoming essential in modern healthcare, with Intuitive Surgical and Stryker leading the market [1][2] - Both companies are heavily investing in innovation and global expansion, making them attractive for investors [2] Market Position and Differentiation - Intuitive Surgical pioneered robotic surgery with the da Vinci platform, while Stryker entered the market through the acquisition of Mako Surgical [3] - Intuitive holds nearly 80% of global surgical robotics volume, contrasting with Stryker's focus on orthopedic robotics with over 1.5 million Mako procedures [4] Revenue & Growth Trends - Intuitive's Q1 2025 revenues increased by 19% to $2.25 billion, with da Vinci procedures growing by 17% [5] - Stryker's MedSurg/Neurotechnology sales rose by 10.6% to $3.89 billion in Q4 2024, while Orthopaedics climbed by 10.8% to $2.55 billion [5] - The global robotic surgery market is projected to grow at a CAGR of 16.5% through 2029, driven by minimally invasive trends and aging populations [6] Estimates Comparison for ISRG & SYK - Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 7.1% respectively [7] - Zacks Consensus Estimate for Stryker's 2025 sales and EPS implies a year-over-year improvement of 8.6% and 10.4% respectively [10] Innovation Driving Growth - Intuitive Surgical is investing in next-generation platforms like the Ion endoluminal system for robotic bronchoscopy [12] - Stryker is enhancing its Mako SmartRobotics suite with AI-driven 3D CT planning and AccuStop haptic feedback [13] Price Performance & Valuation - Year-to-date price performance shows ISRG shares have lost 1.5%, while SYK shares have gained 1.8% [15] - Intuitive Surgical's dominance and sustainable revenue growth position it well, while Stryker's innovations fuel growth in the joint-replacement robotics niche [17] Zacks Rank & Style Score - Both companies currently hold a Zacks Rank 3 (Hold), complicating the investment decision [18] - ISRG's style score of 'F' indicates expensive valuation and low growth potential, while SYK's style score of 'C' suggests strong growth prospects [19]

Core Insights - Lifeward Ltd. has received approval from a major U.S. health insurance company for the ReWalk 7 Personal Exoskeleton, marking a significant step in expanding access for individuals with spinal cord injuries (SCI) [1][2] - The approval follows the Centers for Medicare & Medicaid Services (CMS) establishing a reimbursement pathway for personal exoskeletons in 2024, which is expected to enhance access for Medicare beneficiaries, who represent about one-third of individuals living with SCI [2][3] Company Overview - Lifeward is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [4] - The company has launched the ReWalk 7, a device designed to assist paralyzed individuals in standing, walking, and navigating everyday environments [3][4] Market Context - The decision by a major commercial health insurer to cover the ReWalk 7 is seen as a pivotal moment that could encourage other insurers to follow suit, thereby solidifying Lifeward's growth trajectory [2][3] - The ReWalk 7 received FDA clearance in March 2025 and was launched for sales in the U.S. on April 15, 2025, indicating a timely entry into the market [1][3]

Core Insights - Sequel Med Tech and Senseonics have announced a commercial development agreement to integrate the twiist Automated Insulin Delivery (AID) System with Senseonics' Eversense 365 CGM system, making it the first AID system compatible with a one-year CGM [2][3][5] - The integration aims to enhance diabetes management for individuals with type 1 diabetes by providing more tools for glucose control, convenience, and personalization [3][5] - The twiist AID System is designed to automatically adjust insulin delivery based on real-time sensor readings, offering flexibility in diabetes management [6][8] Company Overview - Sequel Med Tech is focused on developing innovative insulin delivery technologies and aims to simplify disease management through advanced systems [8] - Senseonics specializes in long-term implantable glucose monitoring systems, with the Eversense 365 being the only implantable CGM that offers continuous monitoring for up to one year [9][11] - The collaboration between Sequel and Senseonics represents a significant advancement in diabetes care, providing users with a comprehensive solution that combines advanced pump, algorithm, and sensor technologies [4][5] Product Details - The twiist AID System is FDA-cleared for individuals aged six and up with type 1 diabetes, allowing for precise insulin delivery tailored to individual needs [6] - Eversense 365 received FDA clearance as an integrated continuous glucose monitoring system, enabling its use within automated insulin delivery systems [5][10] - The integration of twiist and Eversense 365 is expected to be commercially available in Q3 2025, enhancing the options available for diabetes management [5][6]

Core Viewpoint - Revvity, Inc. reported strong first-quarter 2025 results with adjusted EPS of $1.01, exceeding estimates and showing year-over-year improvement [1][9] Financial Performance - Adjusted EPS of $1.01 beat the Zacks Consensus Estimate of 96 cents by 5.2% and improved 3.1% from the previous year [1] - Revenues reached $664.7 million, up 2.3% year over year and 4% organically, surpassing the Zacks Consensus Estimate by 0.4% [2] - GAAP EPS from continuing operations was 35 cents, compared to 21 cents in the prior-year period [1] Segment Analysis - Life Sciences segment revenues totaled $340 million, up 2% organically from the previous year, with adjusted operating income of $106 million, a 5% increase [3] - Diagnostics segment revenues were $324 million, reflecting a 3% year-over-year increase, with a 5% organic growth [3] Margin and Expense Analysis - Selling, general and administrative expenses were $249.7 million, down 4.2% year over year, while research and development expenses were $53.6 million, down 6.4% [5] - Adjusted operating income improved 2.5% to $169.9 million, with an adjusted operating margin of 25.6%, expanding 10 basis points [5] Financial Position - Cash and cash equivalents at the end of Q1 2025 were $1.14 billion, slightly down from $1.16 billion at the end of the previous quarter [6] - Net cash used in operating activities was $134.1 million, compared to $150.1 million in the year-ago quarter [6] 2025 Guidance - The company reiterated its earnings outlook, expecting adjusted EPS in the range of $4.90-$5.00, and updated revenue guidance to $2.83-$2.87 billion [7] - The previous revenue guidance was $2.80-$2.85 billion, with the Zacks Consensus Estimate for EPS and revenues at $4.93 and $2.82 billion, respectively [7] Market Reaction and Outlook - Shares of RVTY rose 5.9% in pre-market trading, although the stock has declined 14.6% year-to-date compared to the industry's 1.6% decline [9] - The company is well-positioned to navigate challenges and capitalize on opportunities, with solid execution across both segments [10] Recent Developments - The launch of EUROIMMUN's Anti-Measles Virus ELISA 2.0 in Europe is expected to drive additional sales [11] - FDA approval for the Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test will facilitate commercialization in the U.S. market [12]

Core Insights - Hologic, Inc. is expected to report solid financial performance in its fiscal 2025 second quarter, particularly in the GYN Surgical segment, driven by international strength and contributions from its Diagnostics division [1][3][6] GYN Surgical Segment - The GYN Surgical division is projected to be the top performer, with a 20% increase in international sales in the previous quarter, driven by the MyoSure and NovaSure devices in Europe [3][5] - The tuck-in acquisition of Gynesonics is expected to enhance sales through the company's extensive GYN sales force, contributing to overall revenue growth [4] - Revenue growth for the GYN Surgical segment is projected at 3% compared to the same quarter in fiscal 2024 [5] Diagnostics Segment - The Diagnostics division is anticipated to show strong performance, primarily due to the core molecular diagnostics business, with ongoing adoption of the BV/CV/TV assay on the Panther platform [6][8] - The Aptima SARS-CoV-2 assay received full FDA clearance, which is expected to bolster confidence in testing and contribute to growth [7] - Modest revenue growth of 0.5% is projected for the Diagnostics segment in the upcoming quarter [8] Breast Health Segment - The Breast Health segment is expected to face challenges, with a projected revenue decrease of 3.6% due to capital equipment softness [9][11] - Service revenues are likely to remain solid, accounting for 40% of Breast Health sales, supported by the Interventional breast business and the addition of Endomagnetics [10] - The CE mark received for Affirm Contrast Biopsy Software is expected to expand access across Europe, enhancing the segment's offerings [10]

三轴全向踝关节康复机械人，拍摄：实习生莫林衛 蔡璟补充道，这些丰富的医疗数据为人工智能模型的开发提供了宝贵的资源，香港可以充分利用内地的 医疗数据优势，在人工智能模型开发过程中更好地实现技术落地与应用。通过充分利用内地的医疗数 据，企业能够开发出更具针对性和实用性的产品，更好地满足市场需求。这种优势不仅为香港的科技企 业带来了发展机遇，也为全球医疗科技的发展提供了新的思路和方向。 蔡璟团队研发的人工智能系统，可自动分析患者CT影像生成肺部功能影像，并通过"功能引导"放射治 疗技术设计个性化方案，降低对高功能区域的放射损伤。该系统采用尖端算法训练模型，兼容主流放疗 设备，目前正在香港和内地医院开展临床测试，并计划扩展至肝脑肿瘤治疗。 本次分享会上，香港理工大学武汉科技创新研究院院长何明光带来了其团队的最新成果，该产品创新应 用生成式AI，仅凭普通眼底照片即可生成高精度血管造影影像，该产品现于粤港澳大湾区顶尖机构进 行多中心试验；南京技术创新研究院院长张丹则带来了其团队首创的三轴全向踝关节康复机械人，该设 备正与上海华山医院合作临床测试，未来将结合AI提供个性化方案，并拟扩展至肩手关节康复领域。 蔡璟团队研发的自 ...

Core Insights - Medtronic announced positive clinical outcomes from studies on atrial fibrillation (AFib) patients using the Affera™ technologies, including the Sphere-360™ and Sphere-9™ catheters [1][6] Group 1: Sphere-360 Study - The Sphere-360 catheter demonstrated an 88% freedom from arrhythmia recurrence and 98% durable pulmonary vein isolation (PVI) in a one-year study [2] - No safety events were reported in the subgroup treated with the optimized waveform, highlighting the safety profile of the Sphere-360 [2] - The Sphere-360 catheter features a conformable lattice design and is integrated with the Affera Mapping and Ablation System, utilizing the smallest sheath in single-shot PFA technology at 8.5 Fr [2][3] Group 2: Sphere-9 Catheter - The Sphere-9 catheter was shown to safely create linear lesions in persistent AF patients, enhancing the chances of restoring normal heart rhythm [4] - This catheter is part of the Affera system, which received FDA approval in October 2024, indicating its efficacy in persistent AF treatment [4] Group 3: Medtronic's Position and Future Plans - Medtronic plans to initiate a U.S. pivotal trial for the Sphere-360 catheter later in the year, indicating ongoing commitment to innovation in AFib treatment [3] - The company is the only one offering two PFA solutions, with the PulseSelect™ system already available in over 30 countries, showcasing its leadership in the electrophysiology market [5] - Medtronic continues to expand the Affera system's availability globally, with current access in Europe, Australia, and New Zealand [5]

Core Viewpoint - GE HealthCare Technologies, Inc. (GEHC) is positioned for growth due to its focus on innovations, strong fourth-quarter 2024 performance, and acquisitions, despite facing geopolitical tensions and competition [1] Company Overview - GEHC has a market capitalization of $29.71 billion and projects a 6.2% growth over the next five years, maintaining strong performance with a trailing four-quarter average earnings surprise of 6.17% [2] Factors Favoring Growth - Innovations Supporting Growth: GEHC's commitment to innovation has led to significant improvements, including the launch of Invenia Automated Breast Ultrasound Premium, which utilizes advanced AI for enhanced screening [3] - Recent launches include the AltiX AI.i edition for cardiac procedures, expected to improve efficiency and precision in care [4] - The Genesis portfolio, a cloud-based imaging software solution, aims to modernize healthcare data management and reduce operational costs [5] - The Freelium platform, unveiled at ECR 2025, promotes sustainability in MR imaging by using less than 1% of helium compared to traditional systems [6] - The company received FDA 510(k) clearance for updated Voluson Expert Series ultrasound systems, enhancing women's healthcare with superior image quality and ergonomic design [8] Acquisitions & Partnerships - GEHC is focused on partnerships and acquisitions to attract long-term customers and drive growth, including an expanded collaboration with NVIDIA to develop AI-driven healthcare solutions [9][10] - Strategic collaborations with the University of California, San Francisco, and Sutter Health aim to improve access to advanced imaging and streamline care coordination [11] Financial Performance - GEHC reported strong fourth-quarter 2024 results, with total company orders increasing 6% organically year over year, driven by strength in the U.S. market across all segments [12] - The net income margin improved to 13.5%, up 580 basis points from the prior year, due to productivity and pricing benefits [12] Challenges - GEHC faces potential challenges from new U.S. tariffs on Chinese imports, which may impact its cost structure and profitability, with an expected 10-basis-point hit to the adjusted EBIT margin [13] Estimate Trends - The Zacks Consensus Estimate for GEHC's earnings for fiscal 2025 remains stable at $4.70 per share, with first-quarter fiscal 2025 revenues estimated at $4.66 billion, indicating a 0.2% improvement year over year [14]

Group 1 - The core idea of the news is the integration of AI technology in grassroots healthcare services in Wuyishan City, enhancing chronic disease prevention and management for the elderly and high-risk populations [1][3][5] - Wuyishan City has launched a free health check-up program for individuals aged 65 and above, incorporating new tests for glycosylated hemoglobin and AI retinal screening, creating a closed-loop system for chronic disease management [3][5] - As of early April, 2,228 diabetes patients have undergone screenings for diabetic retinopathy and glaucoma, with 296 high-risk cases identified, allowing timely medical intervention [3] Group 2 - The local health bureau has implemented a three-year action plan for integrated chronic disease management, focusing on expanding and enhancing services for diabetes patients through AI retinal examinations [5][7] - The Airdoc-AIFUNDUS 2.0 software has received certification from the National Medical Products Administration (NMPA), enhancing diagnostic capabilities for various eye diseases in primary healthcare settings [7] - The integration of AI technology is expected to make grassroots healthcare services more intelligent and precise, contributing to the "Healthy China" initiative and improving access to quality medical resources [7]